⚠️ Our website is currently being updated — something new is coming! 🚀
In the meantime, follow us on LinkedIn for the latest updates.
An allogeneic platform designed to generate First-In-Class Tumors antigen-focused immunotherapies.
Changing a paradigm in oncology
of patients currently undergoing
treatment for solid tumors will experience treatment failure.
Our mission at Brenus is to fight evolving diseases in cold solid tumors, which is currently the biggest unmet need in oncology.
The efficacy of current approaches is compromised by no anticipating tumor plasticity and resistances mechanisms.
Strict and AI assisted selection of Specific allogeneic Tumor cell lines to be the most representative of the targeted indication.
Our STC manufacturing overpasses current approaches by covering a broad & higher-quality range of tumor antigens.
Haptenation process is a proven immunogenic tagging** sustainably boosting antigen’s immune recognition. It’s safely ensure immune system activation.
STC 1010
targeting a huge unmet need and adressing solution for colorectal cancer patients
STC Platform
mimicking patient’s relapsing condition and generating first-in-class immunotherapy with limitless potential
MATWIN 2021 award
Finalist 2022
BIOLABS MASTERCLASS
Boston 2022
2022 PRIX GALIEN USA AWARD NOMINEE
"Best startup in the Pharmaceutical or Biotech industry"
ENRICH IN USA 2022 award
MATWIN 2021 award
Finalist 2022
BIOLABS MASTERCLASS
Boston 2022
2022 PRIX GALIEN USA AWARD NOMINEE
"Best startup in the Pharmaceutical or Biotech industry"
ENRICH IN USA 2022 award
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
